Neo-Eunomin (Chlormadinone Acetate, Ethinylestradiol)

The formulation pairs ethinylestradiol, a synthetic estrogen, with chlormadinone acetate, a progestogen. The estrogen stabilises the endometrial lining, while the progestogen suppresses the mid‑cycle surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH), preventing ovulation. It also thickens cervical mucus and alters the endometrium, reducing the chance of fertilisation and implantation.

The dosage regimen for Neo-Eunomin is determined by the prescribing clinician based on the product’s labeling and the patient’s individual needs. Typically, combined oral contraceptives are taken once daily for a defined cycle, but the exact schedule and pack size should be confirmed by a qualified healthcare professional.

Neo-Eunomin is not intended for use during pregnancy; if pregnancy occurs, the product should be discontinued immediately. Regarding breastfeeding, the decision to continue or stop the contraceptive should be made by a healthcare provider, weighing the benefits of contraception against any potential exposure to the infant through breast milk.

To place an order, submit an enquiry on the Neo‑Eunomin product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After validation, the sales team provides pricing, availability, shipping details (including any cold‑chain requirements) and assists with import documentation.

Neo‑Eunomin contains chlormadinone acetate as the progestogenic component, which offers a distinct receptor profile compared with other progestins such as levonorgestrel or desogestrel. This may influence side‑effect patterns, such as a lower incidence of androgenic effects. Efficacy in preventing pregnancy is comparable across approved combined oral contraceptives when taken correctly.

Neo‑Eunomin tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack to protect them from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Neo‑Eunomin is taken orally, usually once daily at the same time each day. The typical regimen follows a 21‑day active tablet sequence followed by a 7‑day pill‑free interval or placebo tablets, during which withdrawal bleeding occurs. Patients should follow the specific instructions provided by their prescriber.

Serious risks include venous thromboembolism, arterial thrombosis such as stroke or myocardial infarction, and severe allergic reactions. These events are rare but can be life‑threatening, especially in women with pre‑existing cardiovascular risk factors, smoking history, or certain genetic predispositions. Prompt medical attention is required if symptoms suggest a thrombotic event.

Neo‑Eunomin is contraindicated in women with a history of thromboembolic disorders, uncontrolled hypertension, known or suspected breast cancer, active liver disease, or those who are pregnant. It should also be avoided by women over 35 who smoke heavily and by individuals with known hypersensitivity to any component of the formulation.